Press release
Rheumatoid Arthritis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | SinoMab (SM03), RemeGen (RC18), CeleCor (Zalunfiban), Abbvie (ABBV-3373), Horizon Therapeutics, Synact, Philogen (Dekavil)
"Rheumatoid Arthritis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Rheumatoid Arthritis Therapeutics Market.
The report provides a detailed description of the Rheumatoid Arthritis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Rheumatoid Arthritis Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Rheumatoid Arthritis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Rheumatoid Arthritis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rheumatoid Arthritis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Rheumatoid Arthritis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Rheumatoid Arthritis treatment market.
Learn More about the Clinical and Commercial Development Activities in the Rheumatoid Arthritis Therapeutics Domain:
https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Rheumatoid Arthritis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Request for Sample PDF to Understand More About the Rheumatoid Arthritis Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Rheumatoid Arthritis Therapeutics Analysis
Rheumatoid Arthritis is an autoimmune disease for which several effective treatment options are present. Currently, there are three primary treatment options for severe and advancing Rheumatoid Arthritis which include DMARDs, NSAIDs, and corticosteroids. Early treatment of Rheumatoid Arthritis patients with DMARDs significantly decreases these complications. Methotrexate is an excellent, economical first-line DMARD used to treat a majority of Rheumatoid Arthritis patients. While most patients respond well to MTX, many continue to have active disease.
Currently, there are approx. 95+ key companies are developing therapies for Rheumatoid Arthritis. RHEACELL is leading the therapeutics market with its Rheumatoid Arthritis drug candidates in the most advanced stage of clinical development.
Rheumatoid Arthritis Companies in the Therapeutics Market Include:
I-Mab Biopharma Co. Ltd., ICMBIO, IGM Biosciences, Inc., Iltoo Pharma, Imcyse, Immutep Limited, Innocare Pharma Australia Pty Ltd, Intrinsic Medicine, Janssen Research & Development, Jiangsu Hengrui Medicine, Jubilant Therapeutics, Kangstem Biotech, Kiniksa Pharmaceuticals, Ltd., KLUS Pharma, Kolon TissueGene, Kymera Therapeutics, Landos Biopharma, Lynk Pharmaceuticals, Lysatpharma GmbH, Mesoblast, MetrioPharm, Minghui Pharmaceutical Pty Ltd, Modern Biosciences, MyMD Pharmaceuticals, Neutrolis Therapeutics, Novartis, NovImmune, Nurix, Oryn Therapeutics, Pfizer, Philogen, PrecisionLife, R-Pharm, Regen BioPharma Inc., RemeGen, Revolo Biotherapeutics, RheumaGen, ROS Therapeutics, Rottapharm Biotech, SciRhom, Servatus Biopharmaceuticals, SFA Therapeutics, Silo Pharma, SinoMab Bioscience Ltd, Sonoma Biotherapeutics, Sorrento Therapeutics, Synact Pharma, Synermore Biologics Co., Ltd., Taiho Pharmaceutical, Teijin Pharma, Tiziana Life Sciences, Vaccinex Inc., Vyne Therapeutics, Worg Pharmaceuticals, Yuyu Pharma, Inc., and many others.
Emerging and Marketed Rheumatoid Arthritis Therapies Covered in the Report Include:
• SM03: SinoMab
• SHR0302: Jiangsu Hengrui Medicine
• RC18: RemeGen
• Zalunfiban: CeleCor Therapeutics
• ABBV-3373: Abbvie
• Dazodalibep: Horizon Therapeutics
• AP1189: Synact Pharma
• Dekavil: Philogen
And Many Others
Get an in-depth Assessment of the Emerging Therapies and Rheumatoid Arthritis Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Rheumatoid Arthritis Current Treatment Patterns
4. Rheumatoid Arthritis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Rheumatoid Arthritis Late-Stage Products (Phase-III)
7. Rheumatoid Arthritis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Rheumatoid Arthritis Discontinued Products
13. Rheumatoid Arthritis Product Profiles
14. Rheumatoid Arthritis Companies
15. Rheumatoid Arthritis Drugs
16. Dormant and Discontinued Products
17. Rheumatoid Arthritis Unmet Needs
18. Rheumatoid Arthritis Future Perspectives
19. Rheumatoid Arthritis Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Erectile Dysfunction Market
https://www.delveinsight.com/report-store/erectile-dysfunction-market
Varicose Ulcer Market
https://www.delveinsight.com/report-store/varicose-ulcer-market
Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Pipeline Insight
https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight
Stereotactic Surgery Devices Market
https://www.delveinsight.com/report-store/stereotactic-surgery-devices-market
Acute lymphocytic leukemia (ALL) Market
https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market
Eczema Market
https://www.delveinsight.com/report-store/eczema-market
Traumatic Brain Injury Market
https://www.delveinsight.com/report-store/traumatic-brain-injury-market
Hemostats Market
https://www.delveinsight.com/report-store/hemostats-market
Gastroesophageal Reflux Disease (GERD) Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
Peripheral Vascular Devices Market
https://www.delveinsight.com/report-store/peripheral-vascular-devices-market
Obesity Market
https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market
Urinary Incontinence Market
https://www.delveinsight.com/report-store/urinary-incontinence-market
Hemostasis Market
https://www.delveinsight.com/report-store/hemostasis-market
Intracardiac Echocardiography Devices Market
https://www.delveinsight.com/report-store/intracardiac-echocardiography-devices-market
Emphysema Market
https://www.delveinsight.com/report-store/emphysema-market
Factor Xa Inhibitor Market
https://www.delveinsight.com/report-store/factor-xa-inhibitor-market
Undifferentiated Pleomorphic Sarcoma Market
https://www.delveinsight.com/report-store/undifferentiated-pleomorphic-sarcoma-market
Carcinoid Tumor Syndrome Market
https://www.delveinsight.com/report-store/carcinoid-tumor-syndrome-market
Primary Progressive Multiple Sclerosis (PPMS) Market
https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market
Thalassemia Market
https://www.delveinsight.com/report-store/thalassemia-market
Preeclampsia Market
https://www.delveinsight.com/report-store/preeclampsia-market
Chronic Periodontitis Market
https://www.delveinsight.com/report-store/chronic-periodontitis-market
Cryptococcosis Market
https://www.delveinsight.com/report-store/cryptococcosis-market
Exocrine Pancreatic Insufficiency Market
https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-market
Papilloma MarketRespiratory Distress Syndrome Market
https://www.delveinsight.com/report-store/respiratory-distress-syndrome-market
Sinusitis Market
https://www.delveinsight.com/report-store/sinusitis-market
Childhood Atropine For Myopia Progression Market
https://www.delveinsight.com/report-store/childhood-atropine-for-myopia-progression-market
Cushing's Syndrome Market
https://www.delveinsight.com/report-store/cushings-syndrome-market
Skin Burns Market
https://www.delveinsight.com/report-store/skin-burns-market
Adeno-Associated Virus Vectors in Gene Therapy Market
https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market
Autism Spectrum Disorder Market
https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rheumatoid Arthritis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | SinoMab (SM03), RemeGen (RC18), CeleCor (Zalunfiban), Abbvie (ABBV-3373), Horizon Therapeutics, Synact, Philogen (Dekavil) here
News-ID: 3152044 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Rheumatoid
Rheumatoid Arthritis Pipeline Outlook Report 2024
DelveInsight's, "Rheumatoid Arthritis Pipeline Insight 2024" report provides comprehensive insights about 95+ companies and 100+ pipeline drugs in the Rheumatoid Arthritis pipeline landscape. It covers the Rheumatoid Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rheumatoid Arthritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the…
Rheumatoid Arthritis Therapeutics Market - Relieving Pain, Restoring Mobility: R …
Newark, New Castle, USA: The "Rheumatoid Arthritis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Rheumatoid Arthritis Therapeutics Market: https://www.growthplusreports.com/report/rheumatoid-arthritis-therapeutics-market/7891
This latest report researches the industry structure,…
How To Cure Rheumatoid Arthritis 2021 ?
Grocare® launches new kit to manage Rheumatoid Arthritis
- New findings support research-based kit for management of Rheumatoid Arthritis
Pune, May 13, 2021: Pune-based Grocare® has recently launched an advanced research-based kit that alleviates and controls Rheumatoid Arthritis, conditions. This kit contains Absogen®, GC® and Acidim® designed to correct mitochondrial imbalance, build immunity and balance PH, respectively.
Grocare® is a pharmaceutical company that has conducted extensive research on Rheumatoid Arthritis. The company’s data…
Major Advancements| Competitor Landscape: Rheumatoid Arthritis
Researchmoz added Most up-to-date research on "Competitor Landscape: Rheumatoid Arthritis" to its huge collection of research reports.
Competitor Landscape: Rheumatoid Arthritis
Summary
Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Rheumatoid Arthritis (RA) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during…
Rheumatoid Arthritis Drug Market Rheumatoid Arthritis Clinical Pipeline Report 2 …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Antirheumatoids: Call of Rheumatoid Arthritis
1.1 Prologue towards Rheumatoid Arthritis
1.2 Obtainable Treatment for Rheumatoid Arthritis
Molecular Mechanism of Antirheumatoids
2.1 Purpose of DMARDs in Rheumatoid Arthritis
2.2 Role of Biological Agents in Rheumatoid Arthritis
2.2.1 TNF- Inhibitors
2.2.2 Interleukin -1 and IL-6 Blockers
Classification of Rheumatoid Arthritis Drugs
3.1…
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the…
